专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110112169A1 RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA 审中-公开
标题翻译：用于过敏性RHINITIS和ASTHMA的基于RNAi的治疗方法
公开(公告)号：US20110112169A1
公开(公告)日：2011-05-12
申请号：US12891626
申请日：2010-09-27
申请人： Jianzhu Chen , Herman N. Eisen , Qing Ge
发明人： Jianzhu Chen , Herman N. Eisen , Qing Ge
IPC分类号： A61K31/713 , C07H21/02 , A61K31/7105 , A61P11/00 , A61P11/06 , C12N15/63
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32
摘要： The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
摘要翻译：本发明提供包含用于治疗由（例如，特征为IgE介导的超敏反应）介导的病症和疾病的一种或多种RNAi剂（例如siRNA，shRNA或RNAi载体）的组合物，以及用于鉴定有效的RNAi剂的系统以此目的。该组合物适用于治疗过敏性鼻炎和/或哮喘。在本发明的某些实施方案中，所述RNAi试剂靶向编码选自下组的蛋白质的转录物：FC＆amp;RIα链，FC＆amp; RI＆bgr; 链，c-Kit，Lyn，Syk，ICOS，OX40L，CD40，CD80，CD86，Re1A，Re1B，4-1BB配体，TLR1，TLR2，TLR3，TLR4，TLR5，TLR6，TLR7，TLR8，TLR9，CD83，SLAM ，普通γ链和COX-2。此外，本发明提供RNAi剂/递送剂组合物和使用方法。在本发明的某些实施方案中，包含RNAi试剂的组合物通过呼吸途径递送。

2. 发明申请

US20100204297A1 INFLUENZA THERAPEUTIC 审中-公开
标题翻译：流感治疗
公开(公告)号：US20100204297A1
公开(公告)日：2010-08-12
申请号：US11909413
申请日：2006-03-22
申请人： Jianzhu Chen , Qing Ge , Herman N. Eisen
发明人： Jianzhu Chen , Qing Ge , Herman N. Eisen
IPC分类号： A61K31/713 , C07K7/08 , C07K14/00 , A61P31/16 , C12N15/63
CPC分类号： A61K9/5146 , A61K9/5153 , A61K38/00 , C12N15/111 , C12N15/1131 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/53 , C12N2320/11 , C12N2320/32 , C12N2799/021 , C12N2310/3521
摘要： The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention.
摘要翻译：本发明提供了包含针对流感病毒转录物的RNAi诱导实体和各种递送试剂中的任一种的组合物。本发明还包括使用该组合物抑制流感病毒的生物学活性和/或用于治疗或预防流感的方法。本发明提供了针对分离自人宿主和/或禽类宿主和RNAi诱导实体（例如siRNA和shRNA）的多个流感病毒A菌株的RNAi有利地保守的靶标部分序列，靶向这些有利的保守靶部分。本发明提供了多种核酸，其包含与这些有利保守的靶部分序列中的一种或多种的至少一部分相同或互补的序列。本发明进一步提供了将哺乳动物受试者的器官或组织例如向肺部递送RNAi诱导剂的方法和组合物。还提供了诊断流感和确定流感病毒对RNAi诱导剂抑制的易感性的方法。表达靶向流感基因的RNAi诱导剂的转基因动物是本发明的另一方面。

3. 发明申请

US20090106852A1 Influenza Therapeutic 审中-公开
公开(公告)号：US20090106852A1
公开(公告)日：2009-04-23
申请号：US11952056
申请日：2007-12-06
申请人： Jianzhu Chen , Herman N. Eisen , Qing Ge
发明人： Jianzhu Chen , Herman N. Eisen , Qing Ge
IPC分类号： A01K67/027 , C07H21/02 , A61K31/7105 , A61K9/12 , A61P31/16 , C12N15/63 , C12N5/10
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32 , C12N2799/021
摘要： The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.

4. 发明申请

US20090124567A1 Influenza Therapeutic 审中-公开
标题翻译：流感治疗
公开(公告)号：US20090124567A1
公开(公告)日：2009-05-14
申请号：US12167593
申请日：2008-07-03
申请人： Jianzhu Chen , Herman N. Eisen , Qing Ge
发明人： Jianzhu Chen , Herman N. Eisen , Qing Ge
IPC分类号： A61K31/7052 , C07H21/00 , C12N5/00 , A61P31/16 , C12N15/63 , A01K67/033
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32 , C12N2799/021
摘要： The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
摘要翻译：本发明提供了用于基于RNA干扰（RNAi）现象抑制流感感染和/或复制的方法和组合物以及用于鉴定用于抑制流感病毒的有效siRNA和shRNA以及用于研究流感病毒感染机制的系统的系统。本发明还提供用于抑制感染，致病性和/或其他感染因子的复制的方法和组合物，特别是感染可以从身体外部直接接近的细胞的感染，例如皮肤细胞或粘膜细胞的方法和组合物。此外，本发明提供了包含RNAi诱导实体的组合物，例如靶向流感病毒转录物的siRNA，shRNA或RNAi诱导载体以及各种递送试剂中的任何一种。本发明还包括使用该组合物治疗流感的方法。

5. 发明授权

US07501125B2 Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent 失效
标题翻译：通过热休克蛋白融合蛋白诱导的体内CTL映射到离散的结构域，并且是CD4 + T细胞非依赖性的
公开(公告)号：US07501125B2
公开(公告)日：2009-03-10
申请号：US10885523
申请日：2004-07-01
申请人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Pallister , Jianzhu Chen , Herman N. Eisen , Richard A. Young
发明人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Pallister , Jianzhu Chen , Herman N. Eisen , Richard A. Young
IPC分类号： A61K38/00 , A61K39/00 , A61K39/385 , C07K14/00 , C07K14/005 , C07K14/195
CPC分类号： C07K14/35 , A61K39/00 , A61K47/62 , A61K47/6425 , A61K2039/57 , C07K2319/00
摘要： The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.
摘要翻译：本发明涉及对CD4 + T细胞缺陷的个体中的分子诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到分子的hsp的hsp或一部分ATP结合结构域。在一个实施方案中，本发明涉及在CD4 + T细胞缺乏的个体中治疗HIV的方法，其包括向所述个体施用连接到分子的hsp的一个或多个ATP结合结构域的一部分。本发明还包括在个体中诱导CD4 +独立CTL应答的方法，其包括向所述个体施用连接到分子的hsp的ATP结合结构域的一部分。本发明还涉及在个体中诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到该分子的hsp的ATP结合结构域的一部分。此外，本发明涉及一种组合物，其特征在于与分子连接的hsp的ATP结合域的一部分。

6. 发明授权

US06875435B2 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent 失效
公开(公告)号：US06875435B2
公开(公告)日：2005-04-05
申请号：US09761534
申请日：2001-01-16
申请人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Palliser , Jianzhu Chen , Herman N. Eisen , Richard A. Young
发明人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Palliser , Jianzhu Chen , Herman N. Eisen , Richard A. Young
IPC分类号： A61K45/00 , A61K38/00 , A61K39/00 , A61K39/02 , A61K39/04 , A61K39/12 , A61K39/21 , A61K47/48 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/04 , C07K14/35 , A61K38/04 , A61K39/385
CPC分类号： C07K14/35 , A61K39/00 , A61K47/62 , A61K47/6425 , A61K2039/57 , C07K2319/00
摘要： The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.

7. 发明授权

US5189147A Meterodimeric T lymphocyte receptor antibody 失效
标题翻译：甲基二聚体T淋巴细胞受体抗体
公开(公告)号：US5189147A
公开(公告)日：1993-02-23
申请号：US271216
申请日：1988-11-14
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K39/00 , C07K14/725
CPC分类号： C07K14/7051 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA cones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressedThe U.S. government has rights in this invention by virtue of Grant No. NIH-5-POl-CA28900-04, NIH-5-P30-CA14051-13 and the Arthritis Foundation.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA锥来确定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

8. 发明授权

US5882945A Heterodimeric T lymphocyte receptor 失效
标题翻译：异二聚体T淋巴细胞受体
公开(公告)号：US5882945A
公开(公告)日：1999-03-16
申请号：US262827
申请日：1994-06-21
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K39/00 , C07K14/725 , G01N33/531 , C07K16/28
CPC分类号： C07K14/7051 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由信号肽，可变，连接，恒定，跨膜和细胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

9. 发明授权

US4933185A System for controlled release of biologically active compounds 失效
标题翻译：用于控制释放生物活性化合物的系统
公开(公告)号：US4933185A
公开(公告)日：1990-06-12
申请号：US223887
申请日：1988-07-11
申请人： Margaret A. Wheatley , Robert S. Langer , Herman N. Eisen
发明人： Margaret A. Wheatley , Robert S. Langer , Herman N. Eisen
IPC分类号： A61K9/16 , A61K9/50 , A61K9/62
CPC分类号： A61K9/1664 , A61K9/1652 , A61K9/5031 , Y10S514/885 , Y10S514/963 , Y10T428/2984 , Y10T428/2985
摘要： A controlled release system for delivery of a biologically-active substance. In one embodiment, there is a delayed release of a biologically-active substance. In a second embodiment, the delayed release is preceded by an initial release of biologically active substance. In other variations of the system, there are mulitple discrete releases over time or a continuous slow release combined with discrete releases. The delayed exposure is achieved through the design and construction of the system, specifically, formation of ionically-coated microcapsules around the biologically-active substance in conjunction with a microcapsule core-degrading enzyme. Release of active substance takes place in a burst at such a time as the core degrading enzyme has reduced the core to a molecular weight too low to support enough interaction with the cationic skin to maintain its integrity as a skin. In one example, microcapsules are formed of an ionically cross-linked polysaccharide, calcium alginate, which is further ionically coated with a poly-cationic skin of poly-L-lysine. The capsule coating serves a dual purpose: to control diffusion of the biologically-active substance and the core-degrading enzyme and as a substrate for the mechanism by which the biologically-active substance is released after a time delay.
摘要翻译：用于递送生物活性物质的控制释放系统。在一个实施方案中，存在生物活性物质的延迟释放。在第二个实施方案中，延迟释放之前是生物活性物质的初始释放。在系统的其他变体中，随着时间的推移有多种离散的释放，或者连续的缓慢释放与离散的释放相结合。延迟曝光是通过系统的设计和构建来实现的，具体地说，在微生物活性物质周围与微胶囊核心降解酶结合形成离子涂覆的微胶囊。活性物质的释放在核心降解酶已经将核心降低到分子量太低以至于不能支持与阳离子皮肤的足够相互作用以维持其作为皮肤的完整性的时候发生。在一个实例中，微胶囊由离子交联的多糖，藻酸钙形成，其进一步离子地涂覆有聚-L-赖氨酸的多阳离子皮肤。胶囊涂层具有双重目的：控制生物活性物质和核心降解酶的扩散，并且作为延迟后释放生物活性物质的机制的底物。

10. 发明授权

US5977321A Heterodimeric T lymphocyte receptor subunit 失效
标题翻译：异二聚体T淋巴细胞受体亚单位
公开(公告)号：US5977321A
公开(公告)日：1999-11-02
申请号：US742539
申请日：1991-08-08
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C07K16/28
CPC分类号： C07K16/2809 , C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式